The case against the American healthcare system writes itself. The cost is roughly double what peer countries pay. The outcomes on common metrics are worse. Tens of millions are uninsured or underinsured. Anyone defending the status quo is defending the indefensible. None of that is a defense of the leading reform proposal, which would solve some of the visible problems by gutting the parts of the system that genuinely work.
This isn’t a defense of insurance companies. It’s an argument that the next system needs to preserve more of the current one than its advocates acknowledge.
What American medicine actually does well
The United States runs the largest and most productive biomedical research enterprise in the world. The NIH alone funds around $50 billion in research annually, and pharmaceutical companies based in or operating in the U.S. account for the majority of new drug approvals globally. The pipeline that produced mRNA vaccines, GLP-1 agonists, and CAR-T cell therapies in roughly the same decade is not an accident of geography.
American specialty care, when accessible, is genuinely the global frontier. Cancer survival rates in the U.S. lead most international comparisons. Surgical innovation, complex device implantation, and rare-disease treatment are concentrated here, and physicians from peer countries routinely train in American programs because the case volume and technological availability don’t exist at home.
This is not a complete picture of American medicine. Primary care is poorly funded, public health is chronically underinvested, and the financing system is grotesque. But the apex of the system is real, and it doesn’t survive a transition to flat reimbursement without changes its advocates rarely engage with.
What single-payer reform would change
The pricing pressure that single-payer systems exert is the entire mechanism by which they achieve cost control. Government as monopsony buyer sets reimbursement rates, and providers either accept them or exit the market. In peer countries, this produces lower prices across drugs, devices, and services, with savings consumers benefit from directly.
Applied to the American system at scale, the same mechanism would compress reimbursement enough to materially affect the economics of academic medical centers, specialty practice, and pharmaceutical R&D. Some of that compression is healthy and overdue. Some of it would slow the innovation pipeline that the entire world currently free-rides on, because the marginal new drug only gets developed if the U.S. market provides the return that justifies it.
The reform that would actually work
The serious version of healthcare reform looks less like Medicare for All and more like a hybrid: universal coverage through a public option or expanded marketplace subsidies, aggressive regulation of administrative costs and drug pricing, and preserved private and specialty markets for procedures and treatments where price competition produces better outcomes than monopsony does. Switzerland and Germany operate variants of this, with universal coverage and innovation pipelines that survive.
The takeaway
The honest answer to American healthcare is that it’s two systems welded together: a world-leading apex and a failing base. Reform that fixes the base without dismantling the apex is hard, technical, and politically unsexy, which is why the proposals that get traction are usually neither.
Leave a Reply